Outsmarting Resistance with Rhythm

About this episode

Ben Zeskind discusses Immuneering's innovative approach to treating pancreatic cancer through informatics-driven dosing regimens.

Pancreatic cancer remains one of oncology’s deadliest diagnoses, with standard treatments often offering only transient tumor shrinkage at the cost of grueling side effects and rapid resistance. Immuneering is using transcriptomic and informatics tools to design a MEK inhibitor dosed in intense daily pulses rather than continuously. This approach aims to restore a more normal signaling rhythm in healthy cells while repeatedly ambushing tumors. Ben Zeskind, CEO of Immuneering, discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated.

People in this episode

Guest: Ben Zeskind

Topics covered

• pancreatic cancer
• targeted cancer therapy
• immune response
• MEK inhibitor
• transcriptomic tools

Keywords

• pancreatic cancer
• MEK inhibitor
• tumor resistance
• cancer therapy
• immune response

Mentioned in this episode

Organizations: Immuneering, Levine Media Group

Books & works: Outsmarting Resistance with Rhythm

More episodes of The Bio Report

• Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
• Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
• Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
• Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
• Targeting Cancer Survival Genes in Solid Tumors · May 13, 2026 · 46 min
• Addressing Treatment Gaps in Gout · May 6, 2026 · 37 min